 |
|
Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes
Hyun Goo Kang, Eun Young Choi, Suk Ho Byeon, Sung Soo Kim, Hyoung Jun Koh, Sung Chul Lee, Min Kim
Korean J Ophthalmol. 2018;32(6):451-458. Published online 2018 Nov 27 DOI: https://doi.org/10.3341/kjo.2018.0011
|
|
Citations to this article as recorded by
 Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis
Amparo Ortiz-Seller, Pablo Martorell, Honorio Barranco, Isabel Pascual-Camps, Esteban Morcillo, José L. Ortiz
Survey of Ophthalmology.2024;[Epub] CrossRef Experiencia con el uso de bevacizumab intravítreo en el manejo de la retinopatía del prematuro tipo I en un país latinoamericano
C. Zuluaga-Botero, N. González, G. Escobar, E. Cantor, A. Martínez-Blanco
Archivos de la Sociedad Española de Oftalmología.2024;[Epub] CrossRef Role of anti-TNF in Pediatric Inflammatory Choroidal Neovascularization: A Case Series
Mariana Abi Karam, Severine Guillaum-Czitrom, Isabelle Melki, Cecile Dumaine, Mohamed Ali Gargouri, Selim Fares, Isabelle Cochereau, Cherif Titah
Ocular Immunology and Inflammation.2023; 31(5): 1006. CrossRef Computed Analysis of Retinal Vascular Growth After Bevacizumab Treatment of Retinopathy of Prematurity Until Age 3 Years
J.D. Hammer, Henry Nguyen, Jacqueline Palmer, Sarah Furtney, Swati Agarwal-Sinha
Clinical Therapeutics.2023; 45(1): 4. CrossRef Research Progress on Anti-VEGF Drug Ther-apy for Retinopathy of Prematurity
韵 夏
Advances in Clinical Medicine.2023; 13(05): 7128. CrossRef Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity
Neelam Pawar, D Somyashree, R Meenakshi, Devendra Maheshwari, Syed Mohideen, Mohammed Sithiq Uduman
Indian Journal of Ophthalmology.2023; 71(6): 2561. CrossRef The Long-Term Observation of the Beneficial Effects of Treatment: 0.12 mg Anti-VEGF Monotherapy or Anti-VEGF Combined Therapy and Diode-Laser in Various Stages of Retinopathy of Prematurity—Series of Cases
Monika Modrzejewska, Martyna Nazwalska
Journal of Clinical Medicine.2023; 12(17): 5644. CrossRef Predictive Factors for Retreatment after Intravitreal Ranibizumab Injection to Treat Type 1 Retinopathy of Prematurity
Su Hwan Park, Iksoo Byon, Han Jo Kwon
Journal of the Korean Ophthalmological Society.2023; 64(9): 793. CrossRef The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
Jing Chen, Qingfei Hao, Jing Zhang, Yanna Du, Haoming Chen, Xiuyong Cheng
Italian Journal of Pediatrics.2023;[Epub] CrossRef Comparison of Intravitreal Bevacizumab and Ranibizumab Injections in Aggressive and Type 1 Retinopathy of Prematurity
Kyumin Kang, Ji Hye Jang
Journal of the Korean Ophthalmological Society.2023; 64(9): 784. CrossRef Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment
Elçin Süren, Dilek Özkaya, Ersan Çetinkaya, Mustafa Kalaycı, Kenan Yiğit, Mehmet Fatih Kücük, Muhammet Kazim Erol
International Ophthalmology.2022; 42(6): 1905. CrossRef Factors associated with nonregression of retinopathy of prematurity after laser treatment in western India
SuchetaR Kulkarni, AnanyaSudhir Nibandhe, NileshA Kakade, AnupritaGandhi Bhatt, MadanD Deshpande
Journal of Clinical Ophthalmology and Research.2022; 10(1): 19. CrossRef Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab
Sarkhan ELBAYİYEV, Özdemir ÖZDEMİR, Burak CERAN, Mustafa Şenol AKIN, Fuat Emre CANPOLAT, Suna OGUZ
Turkish Journal of Pediatric Disease.2022; : 1. CrossRef A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity
Emer Chang, Amandeep S. Josan, Ravi Purohit, Chetan K. Patel, Kanmin Xue
Ophthalmology.2022; 129(12): 1389. CrossRef Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
Charis Hoppe, Derick G. Holt, Benjamin F. Arnold, Sumeer Thinda, Sriranjani P. Padmanabhan, Julius T. Oatts
Journal of American Association for Pediatric Ophthalmology and Strabismus.2022; 26(6): 305.e1. CrossRef Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis
Qihang Kong, Wai-kit Ming, Xue-Song Mi
BMJ Open.2021; 11(2): e042384. CrossRef Pathogenetically oriented approach to prevention of retinopathy of prematurity (experimental study)
L.A. Katargina, N.B. Chesnokova, O.V. Beznos, N.A. Osipova, A.Yu. Panova
Vestnik oftal'mologii.2021; 137(3): 26. CrossRef PARADIGM SHIFT IN MANAGEMENT OF ROP: FROM LASERS TO ANTI-VEGF THERAPY
Saroj Sahdev, Purva S. Date
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 57. CrossRef Ursodeoxycholic Acid Halts Pathological Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy
Menaka C. Thounaojam, Ravirajsinh N. Jadeja, Shubhra Rajpurohit, Diana R. Gutsaeva, Brian K. Stansfield, Pamela M. Martin, Manuela Bartoli
Journal of Clinical Medicine.2020; 9(6): 1921. CrossRef Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Fan-Li Lin, Peng-Yuan Wang, Yu-Fan Chuang, Jiang-Hui Wang, Vickie H.Y. Wong, Bang V. Bui, Guei-Sheung Liu
Molecular Therapy.2020; 28(10): 2120. CrossRef Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity
Ana Bety Enríquez, Robert L. Avery, Caroline R. Baumal
Asia-Pacific Journal of Ophthalmology.2020; 9(4): 358. CrossRef Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity
Hyun Goo Kang, Tae Young Kim, Jinu Han, Sueng-Han Han
Korean Journal of Ophthalmology.2019; 33(3): 272. CrossRef
|